Testing a new treatment for methamphetamine use disorder
Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-11073609
This study is looking at how well Troriluzole works to help people who are trying to overcome methamphetamine use, by seeing how it affects their brain and behavior, and it's for anyone dealing with methamphetamine use disorder and possibly opioid use as well.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11073609 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of Troriluzole, a medication aimed at treating methamphetamine use disorder (MUD). The study will assess how this drug impacts brain chemistry and behavior related to methamphetamine use, particularly focusing on its effects on glutamate systems that are disrupted by the drug. Participants will be involved in a controlled environment where their responses to Troriluzole will be monitored, providing valuable data on its potential as a treatment option. The goal is to find a more effective way to help individuals struggling with MUD and co-occurring opioid use disorder.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with methamphetamine use disorder, particularly those who may also have opioid use disorder.
Not a fit: Patients who do not have a history of methamphetamine use or those with other substance use disorders unrelated to methamphetamine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly reduces methamphetamine use and improves recovery outcomes for patients.
How similar studies have performed: Previous research has shown promise in targeting glutamate systems for treating substance use disorders, suggesting that this approach could be effective.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STOOPS, WILLIAM WALTON — UNIVERSITY OF KENTUCKY
- Study coordinator: STOOPS, WILLIAM WALTON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.